// App-Quantinova.ai

219 : Phase I Study of Eltrombopag for Promoting Thrombopoiesis in Patients Undergoing Stem Cell Transplantation After Total Body Irradiation

Researchers

Presenter

  • Gordon L. Phillips II

Principal Investigators

  • Michael W. Becker

  • Louis Constine

  • Jonathan W. Friedberg

  • Jeffrey Andolina

  • Laurie Milner

  • Therese Smudzin

  • Ollivier Hyrien

  • Katie L Dawson

  • Yuhchyau Chen

Medical Centers

  • Radiation Oncology/Pediatrics, University of Rochester Medical Center, Rochester, NY

  • Pediatrics (Neonatology), University of Rochester Medical Center, Rochester, NY

  • Biostatistics and Computational Biology, University of Rochester Medical Center, Rochester, NY

Locations

  • United States

Companies

  • GlaxoSmithKline plc.

Study Components

Therapeutic Area

  • Autoimmune (AI)

Disease

  • Immune thrombocytopenia

  • Acute lung injury

  • Infant Respiratory Distress Syndrome

  • Acute renal failure

  • Pulmonary embolism

  • Thrombocytopenia

  • Venous thrombosis

  • Hypomagnesemia

  • Myelofibrosis

  • Renal insufficiency

  • Hyperglycemia

  • Pericarditis

  • Hypocalcemia

  • Lymphomas

  • Solid malignancies

  • Acute promyelocytic leukemia

  • Graft-versus-host disease

Biomarkers

  • Breakpoint Cluster Region

  • Creatinine

  • Tyrosine 3-Monooxygenase/Tryptophan 5-Monooxygenase Activation Protein Epsilon

Drug/Treatment

  • Eltrombopag

  • Allopurinol

Outcome

  • N/A

Study Design

  • pharmacokinetics

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved